PCVX — Vaxcyte, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1649094 ·
Last close
$50.67
Market Cap
$7.32B
52W High
$63.31
52W Low
$45.30
ADV30
1,600,742
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -345,850,000 | -320,622,000 | 3,348,308,000 | 260,843,000 | 352,294,000 |
| Dec 2025 | 0 | — | -274,283,000 | -246,507,000 | 3,002,717,000 | 173,959,000 | 317,207,000 |
| Sep 2025 | 0 | — | -242,380,000 | -212,830,000 | 3,171,600,000 | 281,080,000 | 278,718,000 |
| Jun 2025 | 0 | — | -226,219,000 | -166,573,000 | 3,305,363,000 | 306,744,000 | 234,029,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-655,577,000
Investing CF
$437,354,000
Financing CF
$2,014,000
CapEx
$-56,973,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.65
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,154,947,000
Inventory
—
Receivables
—
ST Investments
$1,387,000,000
EBIT TTM
$-923,675,000
Pretax Income TTM
$-766,628,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -923,675,000 | -766,628,000 | 3,002,717,000 | 317,207,000 | — | -655,577,000 |
| Dec 2024 | 0 | -569,546,000 | -463,927,000 | 3,511,318,000 | 205,499,000 | — | -452,627,000 |
| Dec 2023 | 0 | -393,041,000 | -402,266,000 | 1,407,917,000 | 167,449,000 | — | -296,790,000 |
| Dec 2022 | 0 | -209,261,000 | -223,485,000 | 1,006,178,000 | 52,565,000 | — | -170,597,000 |
TTM Snapshot
Revenues TTM
$46,552,000
NetIncome TTM
$-195,788,000
OpCashFlow TTM
$0
Assets (Latest)
$3,511,318,000
Forward EPS
$-7.42
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $55.00 · spot: $50.67 · call volume: 87 · put volume: 166
Expected Move to 2026-10-16:
±$12.12
(23.92%) —
implied range
$38.55 –
$62.79
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | $7.32B | $6.99 | — |
| KYMR | Kymera Therapeutics, Inc. | $7.39B | $89.90 | — |
| IMVT | Immunovant, Inc. | $7.13B | $34.71 | — |
| RGEN | REPLIGEN CORP | $7.53B | $133.55 | — |
| QGEN | QIAGEN N.V. | $7.54B | $36.58 | — |
News headlines (Yahoo Finance, 1h cache)
Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study
2026-06-17 15:55 · Yahoo
Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight
2026-06-08 14:01 · Yahoo
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
2026-06-03 14:04 · Yahoo
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
2026-06-02 20:05 · Yahoo
Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments
2026-06-01 06:12 · Yahoo
Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials
2026-05-29 06:40 · Yahoo
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
2026-05-24 14:39 · Yahoo
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
2026-05-24 14:33 · Yahoo
How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise
2026-05-20 20:10 · Yahoo
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
2026-05-19 17:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.